ICERWATCH PUBLIC COMMENTS
VIDEO: ICER on the ‘value’ of treatments for Duchenne
In this space, we've talked a great deal about ICER's failure - often its refusal - to consider the needs and perspectives of patients when determining the value of a new drug or treatment. Patients Rising recently produced a short video about a meeting in 2019 about...
ICYMI: ICER’s Money Problem: A Self-Appointed ‘Drug Pricing Czar’
by Terry Wilcox & William Smith June 22, 2021 While the last year was very difficult for millions of Americans, it was also a period of rapid innovation as leaders in government and the private sector worked to combat a global pandemic. As a result, about half the...
Comments on ICER’s May 14th Draft Evidence Report, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis”
On May 14th, 2021, ICER released a Draft Evidence Report entitled, "JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis.” Patients Rising Now responded to the request for comments on the report. The comments noted that complex health...
Comments on ICER’s May 5 Draft Evidence Report, “Aducanumab for Alzheimer’s Disease: Effectiveness and Value”
On May 5, 2021, ICER released its Draft Evidence Report entitled, “Aducanumab for Alzheimer’s Disease.” Patients Rising Now submitted comments on the draft report. As stated in the comments, the goal for researchers and clinicians – and hope for patients – is to...
New Series: THE LAST WORD
As part of the Patient Access and Affordability Project's ongoing work to hold ICER accountable, we are pleased to announce a new report series, "The Last Word." In this series, Dr. Paul Langley dissects and refutes the conclusions in ICER's most recent Final Evidence...
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.
Comments on ICER's February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that the...
Comments on ICER’s January 22 nd Draft Evidence Report, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value
On January 22, 2021, ICER released its Draft Evidence Report entitled, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value.” Patients Rising Now submitted comments on the draft report. Some of the concerns raised in the letter include the report's...
Draft Evidence Report on Treatments for Anemia in Chronic Kidney Disease
On November 30, 2020, ICER released its Draft Evidence Report entitled, “Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value." Patients Rising Now submitted comments on the draft report. Some of the concerns raised in the letter include the...
Draft Evidence Report on treatments for high cholesterol
On November 12, 2020, ICER released its Draft Evidence Report entitled, “Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value.” Patients Rising Now submitted comments...
Draft Evidence Report on treatments for Hemophilia A
On August 26, 2020, ICER released its Draft Evidence Report entitled, "Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A." Patients Rising Now submitted comments on the draft report raising a number of concerns about both the substance of the report and the...